Owen Wallace's guest appearances

Owen Wallace

Biotech 2050 Podcast

Peter Diamandis

Robert Gould

Jim Burns

David Berry

David Bates

Jim Sullivan

Tim Sweeney

Tim Miller

Andrew Miller

Chris Wright

James Mackay

Atopic Dermatitis

Thomas Barnes

Marty Moore

Raman Sehgal

OwlTail

Robert J. Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015. Prior to joining Epizyme, Robert served as director of novel therapeutics at Broad Institute of MIT and Harvard from 2006 to 2010. Robert spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research. During his time at Merck, Robert was instrumental in advancing more than 20 compounds from discovery into clinical development in multiple therapeutic areas. Robert received a bachelor’s from Spring Arbor University and a Ph.D. from the University of Iowa and completed postdoctoral studies at Johns Hopkins University.Owen Wallace joined Fulcrum in April 2017. He has more than two decades of experience in drug discovery and development across multiple therapeutic areas, including neuroscience, endocrine, infectious, respiratory and rare diseases. He is the co-inventor of seven clinical candidates and has overseen teams who have progressed more than 30 compounds into clinical development. Prior to joining Fulcrum, Owen served as head, global discovery chemistry at Novartis, where he was responsible for teams and projects across multiple sites in several disease areas and the chemical genetics field. Prior to Novartis, he was the site scientific leader with Eli Lilly &amp; Company in the United Kingdom, leading a cross-functional team focusing on Alzheimer’s disease and schizophrenia. Before that, he held research positions at Bristol-Myers Squibb, where he co-initiated a program on a novel mechanism for inhibiting HIV infection that is now in Phase 3 clinical trials. Owen earned his Ph.D. in organic chemistry from Yale University.

Robert J. Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015. Prior to joining Epizyme, Robert served as director of novel therapeutics at Broad Institute of MIT and Harvard from 2006 to 2010. Robert spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research. During his time at Merck, Robert was instrumental in advancing more than 20 compounds from discovery into clinical development in multiple therapeutic areas. Robert received a bachelor’s from Spring Arbor University and a Ph.D. from the University of Iowa and completed postdoctoral studies at Johns Hopkins University.<br><br>Owen Wallace joined Fulcrum in April 2017. He has more than two decades of experience in drug discovery and development across multiple therapeutic areas, including neuroscience, endocrine, infectious, respiratory and rare diseases. He is the co-inventor of seven clinical candidates and has overseen teams who have progressed more than 30 compounds into clinical development. Prior to joining Fulcrum, Owen served as head, global discovery chemistry at Novartis, where he was responsible for teams and projects across multiple sites in several disease areas and the chemical genetics field. Prior to Novartis, he was the site scientific leader with Eli Lilly &amp; Company in the United Kingdom, leading a cross-functional team focusing on Alzheimer’s disease and schizophrenia. Before that, he held research positions at Bristol-Myers Squibb, where he co-initiated a program on a novel mechanism for inhibiting HIV infection that is now in Phase 3 clinical trials. Owen earned his Ph.D. in organic chemistry from Yale University.

12. Robert Gould, PhD, President & CEO, and Owen Wallace, PhD, CSO, Fulcrum Therapeutics